Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 0 · FY2024 0
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company carries out wholesale trade in pharmaceuticals and computer equipment.
Group parent — controls 2 companies · ownership
| Ratio | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|
| Margins | ||||
| Gross Margin | 12.0% | 79.7% | 89.1% | 47.0% |
| EBITDA Margin | 7.9% | 64.1% | -11.6% | 10.1% |
| EBITDAR | 1,008 | 12,848 | -572 | 47 |
| EBITDAR Margin | 9.0% | 66.8% | -11.2% | 13.8% |
| EBIT Margin | 7.6% | 63.6% | -20.0% | 10.1% |
| Net Profit Margin | 6.5% | 62.6% | 34.0% | 10.1% |
| Operating Expense % of Sales | 4.1% | 15.6% | 100.7% | 36.9% |
| Returns | ||||
| Return on Assets (ROA) | 14.8% | 65.8% | 11.6% | 0.3% |
| Return on Equity (ROE) | 77.7% | 92.1% | 17.6% | 0.4% |
| ROIC [EBIT / Invested Capital] | 17.9% | 160.2% | -9.4% | 0.4% |
| Leverage & debt balances | ||||
| Debt-to-Assets | 80.2% | 24.5% | 22.5% | 30.6% |
| Debt-to-Equity | 4.20x | 0.34x | 0.34x | 0.46x |
| Debt-to-EBITDA | 4.44x | 0.36x | N/A | 107.38x |
| Equity-to-Assets | 19.1% | 71.5% | 65.9% | 65.9% |
| Net Debt | 3,806 | -5,435 | 971 | 1,332 |
| Cash & Equivalents | 122 | 9,908 | 2,408 | 2,418 |
| Total Debt | 3,928 | 4,473 | 3,379 | 3,750 |
| Liquidity & working capital | ||||
| Current Ratio | 1.12x | 3.32x | 1.57x | 1.50x |
| Quick Ratio | 0.83x | 3.13x | 1.28x | 1.18x |
| Cash Ratio | 0.03x | 1.90x | 0.47x | 0.50x |
| Total Current Assets | 4,458 | 17,330 | 8,041 | 7,291 |
| Total Current Liabilities | 3,963 | 5,219 | 5,120 | 4,873 |
| Inventory | 1,150 | 986 | 1,484 | 1,557 |
| Trade Receivables | 3,187 | 6,436 | 4,148 | 3,316 |
| Trade Payables | 35 | 746 | 1,741 | 431 |
| Net Working Capital | 495 | 12,112 | 2,921 | 2,418 |
| Net Working Capital % of Revenue | 4.4% | 63.0% | 57.0% | 701.7% |
| Trade Working Capital | 4,301 | 6,676 | 3,892 | 4,442 |
| Trade Working Capital % of Revenue | 38.6% | 34.7% | 75.9% | 1289.1% |
| Change in Trade Working Capital | N/A | 2,375 | N/A | 550 |
| Turnover & efficiency | ||||
| Inventory Turnover | 8.53x | 3.95x | 0.38x | 0.12x |
| Days Inventory Outstanding (DIO) | 42.8 | 92.4 | 972.5 | 3112.5 |
| Receivables Turnover | 3.50x | 2.99x | 1.24x | 0.10x |
| Days Sales Outstanding (DSO) | 104.4 | 122.2 | 295.3 | 3512.4 |
| Payables Turnover | 278.89x | 5.22x | 0.32x | 0.42x |
| Days Payable Outstanding (DPO) | 1.3 | 69.9 | 1140.4 | 860.8 |
| Cash Conversion Cycle | 145.9 days | 144.7 days | 127.3 days | 5764.1 days |
| Asset Turnover | 2.27x | 1.05x | 0.34x | 0.03x |
| Cash flow & dividends | ||||
| Operating Cash Flow | -1,141 | 13,252 | 7,632 | 2,282 |
| Free Cash Flow (OCF − Capex proxy) | -2,233 | 9,204 | 2,054 | 10 |
| Cash Conversion (OCF / EBITDA) | -129.1% | 107.5% | N/A | 6533.8% |
| Dividends Declared | 0 | 0 | 0 | 0 |
| Dividend Payout Ratio | 0.0% | 0.0% | 0.0% | 0.0% |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.